This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (REGN 1.55%) and big pharma company Sanofi (SNY 0.94%) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.
More positive clinical trial data released today.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo